{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T16:04:30Z","timestamp":1759334670605,"version":"build-2065373602"},"reference-count":22,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2016,3,1]],"date-time":"2016-03-01T00:00:00Z","timestamp":1456790400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,3,1]],"date-time":"2016-03-01T00:00:00Z","timestamp":1456790400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal Fran\u00e7ais d'Ophtalmologie"],"published-print":{"date-parts":[[2016,3]]},"DOI":"10.1016\/j.jfo.2015.10.009","type":"journal-article","created":{"date-parts":[[2016,3,16]],"date-time":"2016-03-16T20:43:44Z","timestamp":1458161024000},"page":"255-260","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["\u00c9valuation de l\u2019efficacit\u00e9 de l\u2019aflibercept comme traitement de la d\u00e9g\u00e9n\u00e9rescence maculaire li\u00e9e \u00e0 l\u2019\u00e2ge exsudative chez des patients na\u00effs et \u00ab\u00a0switch\u00e9s\u00a0\u00bb. \u00c0 propos de 86\u00a0cas"],"prefix":"10.1016","volume":"39","author":[{"given":"E.","family":"Maringe","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.","family":"Letesson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Duncombe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Muraine","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"O.","family":"Genevois","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jfo.2015.10.009_bib0005","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1056\/NEJMoa054481","article-title":"Ranibizumab for neovascular age-related macular degeneration","volume":"355","author":"Rosenfeld","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jfo.2015.10.009_bib0010","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1056\/NEJMoa062655","article-title":"Ranibizumab versus verteporfin for neovascular age-related macular degeneration","volume":"355","author":"Brown","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jfo.2015.10.009_bib0015","doi-asserted-by":"crossref","first-page":"2537","DOI":"10.1016\/j.ophtha.2012.09.006","article-title":"Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration","volume":"119","author":"Heier","year":"2012","journal-title":"Ophthalmology"},{"key":"10.1016\/j.jfo.2015.10.009_bib0020","doi-asserted-by":"crossref","first-page":"1897","DOI":"10.1056\/NEJMoa1102673","article-title":"Ranibizumab and bevacizumab for neovascular age-related macular degeneration","volume":"364","author":"CATT Research Group","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jfo.2015.10.009_bib0025","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1016\/j.ophtha.2010.09.004","article-title":"Efficacy and safety of monthly versus quarterly ranibizumab treatment in neovascular age-related macular degeneration: the EXCITE study","volume":"118","author":"Schmidt-Erfurth","year":"2011","journal-title":"Ophthalmology"},{"key":"10.1016\/j.jfo.2015.10.009_bib0030","doi-asserted-by":"crossref","first-page":"2499","DOI":"10.1007\/s00417-013-2338-z","article-title":"Ranibizumab for exudative AMD in a clinical setting: differences between 2007\u00a0and 2010","volume":"251","author":"Cohen","year":"2013","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"10.1016\/j.jfo.2015.10.009_bib0035","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1016\/S0181-5512(07)89602-1","article-title":"[Monitoring anti-VEGF drugs for treatment of exudative AMD]","volume":"30","author":"Cohen","year":"2007","journal-title":"J Fr Ophtalmol"},{"key":"10.1016\/j.jfo.2015.10.009_bib0040","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1016\/j.ophtha.2012.10.014","article-title":"Twelve-month efficacy and safety of 0.5mg or 2.0mg ranibizumab in patients with subfoveal neovascular age-related macular degeneration","volume":"120","author":"Busbee","year":"2013","journal-title":"Ophthalmology"},{"key":"10.1016\/j.jfo.2015.10.009_bib0045","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1097\/IAE.0b013e31827b6324","article-title":"Changes in visual acuity in patients with wet age-related macular degeneration treated with intravitreal ranibizumab in daily clinical practice: the LUMIERE study","volume":"33","author":"Cohen","year":"2013","journal-title":"Retina Phila Pa"},{"key":"10.1016\/j.jfo.2015.10.009_bib0050","doi-asserted-by":"crossref","first-page":"526","DOI":"10.3928\/23258160-20141118-07","article-title":"Response to aflibercept after frequent re-treatment with bevacizumab or ranibizumab in eyes with neovascular AMD","volume":"45","author":"Thorell","year":"2014","journal-title":"Ophthalmic Surg Lasers Imaging Retina"},{"key":"10.1016\/j.jfo.2015.10.009_bib0055","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1007\/s00417-014-2838-5","article-title":"Effects of aflibercept for ranibizumab-resistant neovascular age-related macular degeneration and polypoidal choroidal vasculopathy","volume":"253","author":"Kawashima","year":"2015","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"10.1016\/j.jfo.2015.10.009_bib0060","doi-asserted-by":"crossref","first-page":"394","DOI":"10.3928\/23258160-20140909-03","article-title":"Response to aflibercept in patients with persistent exudation despite prior treatment with bevacizumab or ranibizumab for age-related macular degeneration","volume":"45","author":"Eadie","year":"2014","journal-title":"Ophthalmic Surg Lasers Imaging Retina"},{"key":"10.1016\/j.jfo.2015.10.009_bib0065","doi-asserted-by":"crossref","first-page":"275","DOI":"10.3928\/23258160-20140709-03","article-title":"Intravitreal bevacizumab and aflibercept for the treatment of exudative age-related macular degeneration","volume":"45","author":"Selid","year":"2014","journal-title":"Ophthalmic Surg Lasers Imaging Retina"},{"key":"10.1016\/j.jfo.2015.10.009_bib0070","doi-asserted-by":"crossref","first-page":"273754","DOI":"10.1155\/2014\/273754","article-title":"Visual and anatomical outcomes of intravitreal aflibercept for treatment-resistant neovascular age-related macular degeneration","volume":"2014","author":"Gharbiya","year":"2014","journal-title":"BioMed Res Int"},{"key":"10.1016\/j.jfo.2015.10.009_bib0075","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1136\/bjophthalmol-2013-304829","article-title":"Injection frequency and anatomic outcomes 1\u00a0year following conversion to aflibercept in patients with neovascular age-related macular degeneration","volume":"98","author":"Messenger","year":"2014","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.jfo.2015.10.009_bib0080","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1016\/j.ajo.2009.04.001","article-title":"Results of one-year's treatment with ranibizumab for exudative age-related macular degeneration in a clinical setting","volume":"148","author":"Cohen","year":"2009","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.jfo.2015.10.009_bib0085","doi-asserted-by":"crossref","first-page":"i22","DOI":"10.1136\/bjophthalmol-2013-304798","volume":"98\u00a0Suppl 1","author":"Singh","year":"2014","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.jfo.2015.10.009_bib0090","article-title":"[Change of therapy from ranibizumab to aflibercept for recurrent or persistent exudative age-related macular degeneration.]","author":"Ziegler","year":"2014","journal-title":"Ophthalmol Z Dtsch Ophthalmol Ges"},{"key":"10.1016\/j.jfo.2015.10.009_bib0095","doi-asserted-by":"crossref","first-page":"4971","DOI":"10.1155\/2014\/497178","article-title":"Intravitreal aflibercept outcomes in patients with persistent macular exudate previously treated with bevacizumab and\/or ranibizumab for neovascular age-related macular degeneration","volume":"2014","author":"Griffin","year":"2014","journal-title":"J Ophthalmol"},{"key":"10.1016\/j.jfo.2015.10.009_bib0100","first-page":"895","article-title":"Visual and anatomical outcomes following intravitreal aflibercept in eyes with recalcitrant neovascular age-related macular degeneration: 12-month results","volume":"28","author":"Grewal","year":"2014","journal-title":"Eye Lond Engl"},{"key":"10.1016\/j.jfo.2015.10.009_bib0105","article-title":"Short-term results of switchback from aflibercept to ranibizumab in neovascular age-related macular degeneration in clinical practice","author":"Despreaux","year":"2015","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"10.1016\/j.jfo.2015.10.009_bib0110","doi-asserted-by":"crossref","DOI":"10.1159\/000381221","article-title":"Switch to aflibercept in the treatment of neovascular AMD: one-year results in clinical practice","author":"Pinheiro-Costa","year":"2015","journal-title":"Int Ophtalmol"}],"container-title":["Journal Fran\u00e7ais d'Ophtalmologie"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0181551216000553?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0181551216000553?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T19:05:51Z","timestamp":1759259151000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0181551216000553"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,3]]},"references-count":22,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2016,3]]}},"alternative-id":["S0181551216000553"],"URL":"https:\/\/doi.org\/10.1016\/j.jfo.2015.10.009","relation":{},"ISSN":["0181-5512"],"issn-type":[{"type":"print","value":"0181-5512"}],"subject":[],"published":{"date-parts":[[2016,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"\u00c9valuation de l\u2019efficacit\u00e9 de l\u2019aflibercept comme traitement de la d\u00e9g\u00e9n\u00e9rescence maculaire li\u00e9e \u00e0 l\u2019\u00e2ge exsudative chez des patients na\u00effs et \u00ab\u00a0switch\u00e9s\u00a0\u00bb. \u00c0 propos de 86\u00a0cas","name":"articletitle","label":"Article Title"},{"value":"Journal Fran\u00e7ais d'Ophtalmologie","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jfo.2015.10.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2016 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}